Hair transplant deaths: Cops collect evidence from doc's clinic
Kanpur: Police on Wednesday took Dr Anushka Tiwari into custody in accordance with a court order and escorted her to her clinic to collect evidence in connection with the hair transplant deaths case.
At the clinic, police seized the PRP machine, tools, kit and other equipment, as well as various documents, in Dr Anushka's presence.
During the six-hour period of police custody remand, Dr Anushka lost consciousness three times and also sustained a minor muscle injury on her foot. The police team sent her twice to CHC Kalyanpur for treatment. She was produced in jail around 3pm, where she again lost consciousness and collapsed.
Investigation officer Pushpraj Singh, accompanied by women constables, took Dr Anushka from jail around 9 o'clock in the morning and arrived at her clinic at about 10am. The team remained there for around three hours, searching the reception, office, operation theatre, pantry and all rooms of the clinic. Police took possession of machines, apparatus, an attaché and documents as evidence.
Additional commissioner of police Abhishek Pandey stated that Dr Anushka opened the clinic door while in custody.
Inside was a full hair transplant setup, including a small operation theatre. Machines used in hair transplantation, Platelet Rich Plasma apparatus and various tools were recovered from there.
Dr Anushka holds a BDS degree but also performed hair transplant procedures. She was later taken back to jail after the custody hours.
Dr Anushka allegedly performed hair transplants on two engineers— Vineet Dubey and Mayank Tiwari and both died within 24 hours following their operations. She surrendered before the court on May 26. The police sought her custody after which the court granted them six hours of remand.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
10 hours ago
- Hindustan Times
Six Indo-Canadians among 9 arrested in drug seizure worth $36.5mn
Toronto: Nine people, including six Indo-Canadians, have been arrested and charged in the Greater Toronto Area (GTA) in what local law enforcement described as 'largest drug seizure' in the history of the region. The arrests were made in connection with a transnational cocaine smuggling network, and the operation, 'Project Pelican', was undertaken by the Peel Regional Police (PRP), working with partners including the Canada Border Services Agency (CBSA), the US Drug Enforcement Administration, and US Homeland Security Investigations Border Enforcement Task Force in Detroit. 'The investigation, Project Pelican, marks the largest drug seizure in the service's history – with nearly CAD 50 million ($36.5 million) worth of cocaine seized,' a release from PRP said. Authorities seized 479 kg of bricked cocaine along with two illegal semi-automatic loaded handguns. The investigation started in June 2024. In June 2024, with police probing the ring that was using US-Canada commercial trucking routes, and by November, 'multiple individuals, trucking companies, and storage sites linked to the operation were identified.' As of June 6, nine accused have been arrested and face in total, 35 charges related to firearm and drug offences. They were identified as Hao Tommy Huynh, a 27-year-old resident of Mississauga, Sajgith Yogendrarajah, 31, from Toronto, Manpreet Singh, 44, from Brampton, Philip Tep, 39, from Hamilton, Arvinder Powar, 29, from Brampton, Karamjit Singh, 36, from Caledon, Gurtej Singh, 36, from Caledon, Sartaj Singh 27, from Cambridge and Shiv Onkar Singh, 31, from Georgetown. Between February and May 2025, CBSA intercepted a commercial truck at the Ambassador Bridge in Windsor, leading to the seizure of 127 kilogrammes of cocaine concealed in the trailer and the arrest of the driver, and agency, supported by the Royal Canadian Mounted Police (RCMP), intercepted another truck at the Blue Water Bridge in Point Edward, which led to the seizure of 50 kilogrammes of cocaine hidden within the trailer and the arrest of the driver. 'Additional seizures were also made across the GTA in connection with commercial trucking by Peel Regional Police, some of which included individuals in possession of loaded firearms at the time of arrest,' the release added. 'This seizure marks the largest drug seizure in the history of our service. Organised crime continues to exploit borders and pose serious threats to public safety. However, we remain firmly committed to working with our partners to protect our communities and enhance safety in our region and beyond,' PRP chief Nishan Duraiappah said. Michael Prosia, CBSA's Regional Director General – Southern Ontario, noted, 'These significant seizures and arrests demonstrate the strength of our collaboration with law enforcement partners on both sides of the border. Together, we are committed to dismantling organized crime groups and keeping harmful drugs out of our communities.'
Economic Times
3 days ago
- Economic Times
One cough too many: India's TB fight isn't quite there yet
Agencies A PIB release dated March 24, 2025, says India's TB elimination targets for 2025 are an 80% reduction in incidence and a 90% reduction in deaths, compared with 2015. One moment Anushka (name changed) was a college student. Then her world turned upside down. It started with a persistent cough and high fever. Despite popping meds, it wouldn't go away. Tests followed and then came the news that knocked the stuffing out of her—she had a fatal form of tuberculosis (TB). With scarred lungs, she gasped for each breath. The bacteria had killed her appetite, making her frail and bony. Her skin colour changed—to dark and then grew paler. At 20, her life expectancy dwindled to a few months.'I felt weak,' she recalls, 'and preferred to be alone.'Battling extensively drug-resistant tuberculosis or XDR-TB, a form of the disease in which drugs rarely worked, Anushka's only option was to be loaded each day with scores of tablets and injections. Those came with toxic side effects. For over four years, she moved between government and private hospitals, enduring cycles of failed treatment. Relief came only when she was placed on a salvage regimen—the last option when all other interventions are exhausted—at a Médecins Sans Frontières (MSF) clinic in Govandi, Mumbai. The global humanitarian group offered Anushka a cocktail of bedaquiline, delamanid and imipenem injections, a set of very powerful meds often inaccessible to most Indians due to supply restrictions aimed at curbing drug resistance. Anushka, who has now recovered, recounted her ordeal at MSF's TB Day event in Mumbai on May 12, speaking before an audience of doctors, a quiet smile breaking through years of pain. Her journey to recovery is rare, and alien to millions in India, which reflects a public health system still failing its most vulnerable. India now accounts for more than a quarter of all TB cases reported worldwide. In 2023, the country had 26% of the global TB burden, according to the World Health Organization (WHO). Bending the curve remains difficult despite multiple national programmes. How can India improve?In 2018, when India pledged to eliminate TB by 2025, five years ahead of the set global target, the objective was clear. And progress has been made, too. Between 2015 and 2023, TB incidence (new and relapsed cases per 1 lakh population every year) fell by 18% and deaths by 24%, per is a sign in the right direction, but the number of cases are still astounding, especially when it comes to drug-resistant variants. 'India bears the highest burden of XDR-TB globally, with an estimated 110,000 new cases annually,' says Professor Anil Koul of the London School of Hygiene and Tropical Medicine. A key figure in TB drug research, Koul was part of a Johnson & Johnson team that developed bedaquiline, one of the most effective drugs against resistant TB notes that Covid-19 deepened the crisis, and underfunded research has stalled progress. Of the 27 drugs in clinical trials, none have reached Phase III. Bedaquiline remains the mainstay.A 100-day TB Elimination Challenge was launched by the government in December 2024 to amplify efforts to diagnose and treat TB at the village level, but experts aren't satisfied.'We are not on track,' says Dr Animesh Sinha, chronic care and infectious disease advisor, MSF. 'To meet the 2025 milestones of WHO's End TB strategy, India should achieve a 50% reduction in TB incidence rate and a 75% reduction in the total number of TB deaths compared with 2015.' Although numbers have fallen, the quantum has been woefully short of the target, as WHO numbers suggest.A PIB release dated March 24, 2025, says India's TB elimination targets for 2025 are an 80% reduction in incidence and a 90% reduction in deaths, compared with 2015.A key problem is underreporting emanating from under-diagnosis. India's notification rate (number of TB cases diagnosed and officially reported) has improved from 108 per 100,000 population in 2010 to 166 in 2023, yet many cases, especially in rural areas, go undetected.'In order to address the TB crisis, we have to find the missing cases,' says Sinha. Nonetheless, the 2025 goal helped push TB up the political agenda. Ni-kshay, a digital platform for notification and treatment monitoring, is improving reporting. But without proportionate investment in diagnostics, staffing and drug access, the pace of progress will be inconsistent. Intermittent drug shortages have been reported, and India spent just 2.1% of the National Tuberculosis Elimination Programme budget on diagnostics till 2023-24, an IndiaSpend RTI revealed. 'The 2025 target was always a stretch,' says Koul. 'But it did galvanise government machinery, leading to faster approvals for newer regimens like bedaquiline, speedier rollout across TB centres and more budgetary support, including for nutritional aid.'That said, TB continues to receive only a sliver of public health funding. But even so, he notes, there certainly is a positive trend in fighting back, considering the complexity of the disease and the socioeconomic factors shaping in an ET Morning Brief podcast in January, Dr Urvashi Singh, deputy director-general (TB), Ministry of Health and Family Welfare, said, 'The domestic budget for the national TB programme has increased over five times in the last 10 years.' India, she added, is the only high-burden country where 91% of the programme is backed by domestic detection is often the difference between quick recovery and years of suffering. Goa-based diagnostic device maker Molbio Diagnostics' Truenat, a portable molecular-testing platform, introduced in 2017, expanded diagnostic access, particularly in low-access regions. 'We supplied over 90 lakh testing kits last year and expect to provide 1.25 crore this year,' says Sriram Natarajan, CEO of Molbio, which is working with government and statelevel partners to rollout molecular testing.A Truenat test costs just Rs 640, a fraction of what imported diagnostics demand, says Natarajan. In public health, he argues, the real measure isn't price, but cost-effectiveness, especially when early detection can avert far greater globally approved diagnostics protocols remain out of reach in India. The WHO-recommended urine TBLAM test, used to diagnose TB in HIVpositive patients, is still unavailable in the country, despite successful validation studies in Mumbai in 2022. Registration barriers and lack of supply from manufacturers have led to lack of access, says Leena Menghaney, a public health lawyer based in Delhi. Supplyrelated issues could be because trials in India have yet to conclude, according to industry delays cost precious lives. Late detection risks high transmission rates and complications for patients. Dr Jennifer Furin, infectious diseases clinician, Harvard Medical School, says while Truenat is helpful and the diagnostic pipeline is robust, the outdated and slow systems for approving novel tools in India have a detrimental impact. Furin points to a critical gap: the lack of household-level prevention. Studies, including a 2023 trial published in TheLancet, show that modest nutritional support for families of TB patients can sharply reduce transmission. Another model, published in TheLancet this year, estimates that improving household nutrition alone could prevent nearly 5% of TB deaths by carrying the world's highest TB burden, regulatory reforms have been slow in India. Some gains have been made, but systemic delays continue to blunt the impact of new patients with drug-resistant TB, a new wave of treatment offers hope, but conditions apply. Regimens like a six-month, all-oral combination termed BPaLM— bedaquiline, pretomanid, linezolid and moxifloxacin—have been game-changers, replacing the gruelling 24-month regimens of daily injections and pills. 'These regimens are better tolerated and highly effective, with about 90% of people completing treatment successfully,' says Sinha. While clinicians welcome the government's push for shorter regimens, access remains limited—only 1,700 patients in India have received them, according to Dr Rupak Singla, head of the department of respiratory medicine, National Institute of Tuberculosis and Respiratory Diseases, Delhi, who spoke at the event in Mumbai. Adoption has lagged due to limited access to drug susceptibility testing for newer drugs, which is crucial for choosing an appropriate treatment strategy. The BPaLM regimen can't be given in cases where more than one organ system is involved or in patients with severe extrapulmonary disease, 'both of which are common in India,' according to Dr Alpa Dalal, head of unit, Group of TB Hospitals, Sewri, Mumbai. BPaLM should not be prescribed for patients previously treated with bedaquiline, says Dalal, unless drug susceptibility to bedaquiline and linezolid is says even in extensive pulmonary TB, where studies have shown good outcomes with BPaLM, many clinicians are cautious. In longer regimens, patients with extensive lung involvement have had higher relapse rates, compared with patients with limited disease, she explains, and that concern carries over. A study published in OUP's research platform, Oxford Academic, in March 2025 shows that bedaquiline resistance among previously treated patients can reduce the drug's warn that such resistance could undercut its effectiveness in the long term if not addressed early. But Koul says, 'Bedaquiline has galvanised TB R&D. It will remain a core component of future regimens, unless we see a dramatic rise in resistance in clinical practice.'The economics of care create barriers too. Pricing is a big hurdle. Regimens with imipenem cost thousands of rupees per day. Anushka was treated free by MSF. Else each injection alone, she said, would cost Rs 2,499. Considering the socioeconomic realities of India, perhaps this is where the government could step approach to procurement is problematic too. The country selectively joins pooled procurement platforms like the Global Drug Facility, which could reduce costs. 'India has in the past refused to participate in this, unless they had an emergency,' says policy and procurement, TB is a profoundly social disease, shaped by stigma, poverty and undernutrition. Even the best drugs won't work if care doesn't reach those who need it most. Guidelines may improve and approvals may accelerate but until the system meets people where they are, too many will be left suffered for years before she got cured. Her strength wasn't just in surviving; it was in refusing to give up. 'Even in that condition, I completed my graduation and kept chasing my dreams,' she says. India's TB response must now rise to match that grit, with urgency, equity and compassion.
Time of India
3 days ago
- Time of India
One cough too many: India's TB fight isn't quite there yet
Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads MISSING CASES Tired of too many ads? Remove Ads NEW HOPE, OLD GAPS A CURE WITH ISSUES WHAT NEXT? One moment Anushka (name changed) was a college student. Then her world turned upside down. It started with a persistent cough and high fever. Despite popping meds, it wouldn't go away. Tests followed and then came the news that knocked the stuffing out of her—she had a fatal form of tuberculosis TB ). With scarred lungs, she gasped for each breath. The bacteria had killed her appetite, making her frail and bony. Her skin colour changed—to dark and then grew paler. At 20, her life expectancy dwindled to a few months.'I felt weak,' she recalls, 'and preferred to be alone.'Battling extensively drug-resistant tuberculosis or XDR-TB, a form of the disease in which drugs rarely worked, Anushka's only option was to be loaded each day with scores of tablets and injections. Those came with toxic side effects. For over four years, she moved between government and private hospitals, enduring cycles of failed came only when she was placed on a salvage regimen—the last option when all other interventions are exhausted—at a Médecins Sans Frontières (MSF) clinic in Govandi, Mumbai. The global humanitarian group offered Anushka a cocktail of bedaquiline , delamanid and imipenem injections, a set of very powerful meds often inaccessible to most Indians due to supply restrictions aimed at curbing drug who has now recovered, recounted her ordeal at MSF's TB Day event in Mumbai on May 12, speaking before an audience of doctors, a quiet smile breaking through years of pain. Her journey to recovery is rare, and alien to millions in India, which reflects a public health system still failing its most vulnerable. India now accounts for more than a quarter of all TB cases reported worldwide. In 2023, the country had 26% of the global TB burden, according to the World Health Organization (WHO). Bending the curve remains difficult despite multiple national can India improve?In 2018, when India pledged to eliminate TB by 2025, five years ahead of the set global target, the objective was clear. And progress has been made, too. Between 2015 and 2023, TB incidence (new and relapsed cases per 1 lakh population every year) fell by 18% and deaths by 24%, per is a sign in the right direction, but the number of cases are still astounding, especially when it comes to drug-resistant variants. 'India bears the highest burden of XDR-TB globally, with an estimated 110,000 new cases annually,' says Professor Anil Koul of the London School of Hygiene and Tropical Medicine. A key figure in TB drug research, Koul was part of a Johnson & Johnson team that developed bedaquiline, one of the most effective drugs against resistant TB notes that Covid-19 deepened the crisis, and underfunded research has stalled progress. Of the 27 drugs in clinical trials, none have reached Phase III. Bedaquiline remains the mainstay.A 100-day TB Elimination Challenge was launched by the government in December 2024 to amplify efforts to diagnose and treat TB at the village level, but experts aren't satisfied.'We are not on track,' says Dr Animesh Sinha, chronic care and infectious disease advisor, MSF. 'To meet the 2025 milestones of WHO's End TB strategy, India should achieve a 50% reduction in TB incidence rate and a 75% reduction in the total number of TB deaths compared with 2015.' Although numbers have fallen, the quantum has been woefully short of the target, as WHO numbers suggest.A PIB release dated March 24, 2025, says India's TB elimination targets for 2025 are an 80% reduction in incidence and a 90% reduction in deaths, compared with 2015.A key problem is underreporting emanating from under-diagnosis. India's notification rate (number of TB cases diagnosed and officially reported) has improved from 108 per 100,000 population in 2010 to 166 in 2023, yet many cases, especially in rural areas, go undetected.'In order to address the TB crisis, we have to find the missing cases,' says Sinha. Nonetheless, the 2025 goal helped push TB up the political agenda. Ni-kshay, a digital platform for notification and treatment monitoring, is improving reporting. But without proportionate investment in diagnostics, staffing and drug access, the pace of progress will be drug shortages have been reported, and India spent just 2.1% of the National Tuberculosis Elimination Programme budget on diagnostics till 2023-24, an IndiaSpend RTI revealed.'The 2025 target was always a stretch,' says Koul. 'But it did galvanise government machinery, leading to faster approvals for newer regimens like bedaquiline, speedier rollout across TB centres and more budgetary support, including for nutritional aid.'That said, TB continues to receive only a sliver of public health funding. But even so, he notes, there certainly is a positive trend in fighting back, considering the complexity of the disease and the socioeconomic factors shaping in an ET Morning Brief podcast in January, Dr Urvashi Singh, deputy director-general (TB), Ministry of Health and Family Welfare, said, 'The domestic budget for the national TB programme has increased over five times in the last 10 years.' India, she added, is the only high-burden country where 91% of the programme is backed by domestic detection is often the difference between quick recovery and years of suffering. Goa-based diagnostic device maker Molbio Diagnostics' Truenat, a portable molecular-testing platform, introduced in 2017, expanded diagnostic access, particularly in low-access regions. 'We supplied over 90 lakh testing kits last year and expect to provide 1.25 crore this year,' says Sriram Natarajan, CEO of Molbio, which is working with government and statelevel partners to rollout molecular testing.A Truenat test costs just Rs 640, a fraction of what imported diagnostics demand, says Natarajan. In public health, he argues, the real measure isn't price, but cost-effectiveness, especially when early detection can avert far greater globally approved diagnostics protocols remain out of reach in India. The WHO-recommended urine TBLAM test, used to diagnose TB in HIVpositive patients, is still unavailable in the country, despite successful validation studies in Mumbai in 2022. Registration barriers and lack of supply from manufacturers have led to lack of access, says Leena Menghaney, a public health lawyer based in Delhi. Supplyrelated issues could be because trials in India have yet to conclude, according to industry delays cost precious lives. Late detection risks high transmission rates and complications for patients. Dr Jennifer Furin, infectious diseases clinician, Harvard Medical School, says while Truenat is helpful and the diagnostic pipeline is robust, the outdated and slow systems for approving novel tools in India have a detrimental impact. Furin points to a critical gap: the lack of household-level prevention. Studies, including a 2023 trial published in TheLancet, show that modest nutritional support for families of TB patients can sharply reduce transmission. Another model, published in TheLancet this year, estimates that improving household nutrition alone could prevent nearly 5% of TB deaths by carrying the world's highest TB burden, regulatory reforms have been slow in India. Some gains have been made, but systemic delays continue to blunt the impact of new patients with drug-resistant TB, a new wave of treatment offers hope, but conditions apply. Regimens like a six-month, all-oral combination termed BPaLM— bedaquiline, pretomanid, linezolid and moxifloxacin—have been game-changers, replacing the gruelling 24-month regimens of daily injections and pills. 'These regimens are better tolerated and highly effective, with about 90% of people completing treatment successfully,' says clinicians welcome the government's push for shorter regimens, access remains limited—only 1,700 patients in India have received them, according to Dr Rupak Singla, head of the department of respiratory medicine, National Institute of Tuberculosis and Respiratory Diseases , Delhi, who spoke at the event in Mumbai. Adoption has lagged due to limited access to drug susceptibility testing for newer drugs, which is crucial for choosing an appropriate treatment BPaLM regimen can't be given in cases where more than one organ system is involved or in patients with severe extrapulmonary disease, 'both of which are common in India,' according to Dr Alpa Dalal, head of unit, Group of TB Hospitals, Sewri, Mumbai. BPaLM should not be prescribed for patients previously treated with bedaquiline, says Dalal, unless drug susceptibility to bedaquiline and linezolid is says even in extensive pulmonary TB, where studies have shown good outcomes with BPaLM, many clinicians are cautious. In longer regimens, patients with extensive lung involvement have had higher relapse rates, compared with patients with limited disease, she explains, and that concern carries over. A study published in OUP's research platform, Oxford Academic, in March 2025 shows that bedaquiline resistance among previously treated patients can reduce the drug's warn that such resistance could undercut its effectiveness in the long term if not addressed early. But Koul says, 'Bedaquiline has galvanised TB R&D. It will remain a core component of future regimens, unless we see a dramatic rise in resistance in clinical practice.'The economics of care create barriers too. Pricing is a big hurdle. Regimens with imipenem cost thousands of rupees per day. Anushka was treated free by MSF. Else each injection alone, she said, would cost Rs 2,499. Considering the socioeconomic realities of India, perhaps this is where the government could step approach to procurement is problematic too. The country selectively joins pooled procurement platforms like the Global Drug Facility, which could reduce costs. 'India has in the past refused to participate in this, unless they had an emergency,' says policy and procurement, TB is a profoundly social disease, shaped by stigma, poverty and undernutrition. Even the best drugs won't work if care doesn't reach those who need it most. Guidelines may improve and approvals may accelerate but until the system meets people where they are, too many will be left suffered for years before she got cured. Her strength wasn't just in surviving; it was in refusing to give up. 'Even in that condition, I completed my graduation and kept chasing my dreams,' she says. India's TB response must now rise to match that grit, with urgency, equity and compassion.
